Trial Profile

Phase 2/3 Adaptive Design, Randomized Double-blind Placebo-controlled Study to Evaluate the Safety and Efficacy of DM199 for the Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)

Status: Recruiting

Phase of Trial: Phase II/III

Latest Information Update: 16 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

06 May 2026 According to a DiaMedica Therapeutics media release, an interim analysis remains planned for completion in the fourth quarter of 2026.
30 Mar 2026 According to a DiaMedica Therapeutics media release, this trial is approaching 70% of required interim enrollment, and interim analysis completion is planned in 2H 2026.
12 Nov 2025 According to a DiaMedica Therapeutics media release, enrollment in this trial is nearing 50% of the target of 200 participants for the interim analysis.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com